BRAF and neoplasm: SOX10-mediated FOXD3 upregulation occurs rapidly following BRAF inhibition; however, SOX10-mediated repression of TGFβ/EGFR/PDGFRβ occurs following the prolonged treatment with BRAF inhibitors, suggesting that differential drug-induced transcriptional states may switch SOX10 from an oncogene to a tumour repressor [66].